← Back to China
Sino Biopharmaceutical
1177.HK · Healthcare · Hang Seng · HKD
Latest observation
Q4 2024
Reality Gap Values
RG8 Q4 2024 0.9
RG10 Q4 2024 0.8
RG12 Q4 2024 0.7
Trend (RG10 vs prior period)
- DecliningSupporting Data (Q4 2024)
| Market Capitalisation | HKD 45.8B |
| Tangible Equity (TE) | HKD 30.3B |
| Smoothed Earnings G (4yr avg) | HKD 2.9B |
| Net Income (this period) | HKD 0B |
Values in HKD billions.
Historical RG Overview
| Period | Mkt Cap (HKD B) | TE (HKD B) | RG8 | RG10 | RG12 |
|---|---|---|---|---|---|
| Q4 2024 | 45.8 | 30.3 | 0.9 | 0.8 | 0.7 |
| Q4 2023 | 44.1 | 30.3 | 0.9 | 0.8 | 0.7 |
| Q4 2022 | 66.1 | 30.3 | 0.7 | 0.6 | 0.5 |
RG10 Trend
No chart data available.
Data Note
Computed via yfinance. Historical end-of-quarter closing price × current shares outstanding. Older quarters estimated from annual NI / 4. Approximation.
All data is illustrative and for research purposes only. Not investment advice. Market cap for historical periods approximated as shares outstanding × year-end closing price (H-share basis).